Regulatory Story
Go to market news section View chart   Print
Company PuriCore Plc
TIDM PURI
Headline

Share Option Grant and Blocklisting Update

Released 18:01 12-Feb-2013
Number 7475X18

RNS Number : 7475X
PuriCore Plc
12 February 2013
 



PuriCore plc

 ("PuriCore" or the "Company")

12 February 2013

 

Share Option Grant and Blocklisting Application Update

 

PuriCore (LSE: PURI), the water-based clean technology company, announces today a share option grant, in accordance with the Disclosure and Transparency Rules. On 8 February, PuriCore issued share options to a Company Non-Executive Director as set forth below. The share options have an exercise price of 40p, which is the closing market price of the Company's ordinary shares on 8 February 2013, and a five-year term.

Name and title

Number of share options granted

Vesting

Daniel Hegglin

Non-Executive Director

35,000

Half on 8 February 2014;

half on 8 February 2015

 

In addition, for administrative reasons, the Company has determined that the blocklisting application submitted and announced on 7 February will no longer be required and has therefore withdrawn the application.

 

Enquiries:

FTI Consulting

Susan Quigley / Simon Conway / Victoria Foster Mitchell

+44 (0) 20 7831 3113

 

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control. PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the standard for food safety and are used for floral care in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEDFTIFLIV
Close
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

Share Option Grant and Blocklisting Update - RNS